© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Dupilumab Reduces Specific IgE to Foods at 12 and 24 Months in Small Study
February 28, 2025
AAAAI 2025: Dupilumab was associated with a 56.9% reduction in IgE levels at 12 months and of 73.5% at 24 months, according to results presented at AAAAI 2025.
Perimenopause Symptoms May Affect More Than Half of Women as Young as Age 30
February 28, 2025
Although many women experience symptoms of perimenopause between ages 30 and 35, the majority do not seek medical attention for up to 2 decades, a new study reveals.
American Academy of Dermatology 2025 Prep: A Dermatologist Considers When Atopic Dermatitis Referral from Primary Care is Indicated
February 28, 2025
Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.
Focus on AAD 2025: Dermatologist Mona Shahriari, MD, Highlights the PCP Role in Atopic Dermatitis Care
February 27, 2025
Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.
Zonisamide Shows Promise for Hard-to-Treat Migraine in Children, Adolescents
February 27, 2025
While the data on zonisamide efficacy for migraine in youths is preliminary, all study participants experienced a 66% reduction in headaches after 1 month of treatment.
Measles Claims Life of Unvaccinated Texas Schoolchild, First US Fatality Reported Since 2015
February 27, 2025
A rural west Texas "undervaccinated" Mennonite community is the epicenter of the worst measles outbreak in the state in 30 years, the state health department reported.
sNDA for Roflumilast Cream 0.05% for the Treatment of AD in Children Aged 2 to 5 Years Gets FDA Nod
February 26, 2025
The FDA has set a PDUFA target action date for October 13, 2025, according to Arcutis Biotherapeutics.
Symbravo for Migraine Demonstrates Efficacy Superior to Prior CGRP Inhibitor Treatment in Phase 3 Trial
February 25, 2025
Symbravo, compared with previous CGRP inhibitor therapy, achieved superior response across efficacy measures including pain freedom and improvements in QoL.
Sinaptica Announces Enrollment for Phase 2 Clinical Trial in Early Alzheimer Disease of Dual Neuromodulation System
February 24, 2025
The proprietary combination of 2 neurostimulation modalities deployed simultaneously may enhance efficacy while reducing treatment time by 70%, the company said.
Depression Increases Risk For and Accrual of Long-Term Health Disorders
February 21, 2025
Comorbid conditions accrued at a rate 30% faster among adults with depression than in those without the disorder over a 7-year follow-up period.